Aradigm Corp (ARDM) 0.2600 $ARDM Aradigm Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aradigm Corp (ARDM) 0.2600 $ARDM

Aradigm Announces Fourth Quarter 2013 and Full Year Financial Results
Business Wire - Thu Mar 13, 6:00AM CDT
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014 on February 11
Business Wire - Tue Feb 04, 6:00AM CST
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 16th Annual BIO CEO & Investor Conference 2014 on Tuesday, February 11, 2014, at 10:30 a.m. ET. The event will be held at the Waldorf-Astoria Hotel in New York, New York.

Aradigm Corporation to participate at Biotech Showcase 2014
M2 - Thu Jan 09, 5:41AM CST
Specialist pharmaceutical company Aradigm Corporation (OTC Markets:ARDM) said on Wednesay that it will take part at Biotech Showcase 2014.

Aradigm to Present at Biotech Showcase 2014 on January 14
Business Wire - Wed Jan 08, 5:59AM CST
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at Biotech Showcase 2014 on Tuesday, January 14, 2014, at 11: 30 a.m. Pacific time. The event will be held at Parc 55 Wyndham - Union Square Hotel, San Francisco, California.

Aradigm Corporation elects Dr. Juergen Froehlich as CMO
M2 - Wed Nov 20, 3:00AM CST
Pharmaceutical company Aradigm Corporation (OTC Markets:ARDM) announced on Tuesday that it has hired Dr Juergen Froehlich, MD as its chief medical officer.

Aradigm Announces Appointment of Dr. Juergen Froehlich as Chief Medical Officer
Business Wire - Tue Nov 19, 6:00AM CST
Aradigm Corporation (OTCBB:ARDM) ("Aradigm" or the "Company") today announced that Juergen Froehlich, MD has been appointed as Aradigm's Chief Medical Officer. He joins Aradigm from Vertex Pharmaceuticals where he was Head of Regulatory Affairs, overseeing global submissions and approvals under accelerated review timelines of Kalydeco (ivacaftor) and the granting of two Breakthrough Designations for the orphan indication of cystic fibrosis.

Ohr Pharmaceutical (OHRP) Looks Good: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 7:25AM CST
Ohr Pharmaceutical was a big mover last session, with shares rising over 7% on the day.

LifeSci Advisors Initiates Coverage of Aradigm Corporation
Marketwire - Tue Oct 29, 8:00AM CDT
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Aradigm Corporation (OTCBB: ARDM), an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. Aradigm has granted an exclusive worldwide license to Grifols for its proprietary, once-daily, inhaled liposomal formulations of ciprofloxacin, Pulmaquin(R) and Lipoquin(R). The drugs are being developed to treat severe respiratory diseases such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). The deal provides up to $65 million for developmental and clinical expenses related to the BE indication. Aradigm can receive an additional $25 million in development milestones plus tiered, double-digit royalties.

Aradigm Corporation's net loss widens to USD14.9m in Q3 2013
M2 - Mon Oct 28, 7:32AM CDT
Pharmaceutical company Aradigm Corporation (OTC BB:ARDM.OB) on Friday reported a net loss of USD14.9m (USD0.04 per share) for the third quarter ended 30 September 2013.

Aradigm Announces Third Quarter 2013 Financial Results
Business Wire - Mon Oct 28, 6:00AM CDT
Aradigm Corporation (OTC BB: ARDM.OB) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2013.

Forest's Patent Infringement Lawsuits - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 07, 11:30AM CDT
The company filed an additional patent infringement lawsuit against First Time US Generics for Savella.

Aradigm Announces Changes to Its Board of Directors
Business Wire - Wed Sep 18, 6:00AM CDT
Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm" or the "Company") today announced changes to its Board of Directors, including the retirement of Frank Barker and the appointment of Lafmin Morgan and David Bell.

Sigma-Tau PharmaSource Inc to supply Pulmaquin to Aradigm Corporation
M2 - Tue Sep 17, 9:20AM CDT
Sigma-Tau PharmaSource Inc revealed on Monday the launch of a broad manufacturing services agreement to provide clinical and commercial supplies of Pulmaquin to Aradigm Corporation (OTC BB:ARDM.OB).

Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
Business Wire - Mon Sep 16, 6:00AM CDT
Sigma-Tau PharmaSource, Inc. (a wholly owned subsidiary of Sigma-Tau Pharmaceuticals Inc.), a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation, and Aradigm Corporation (OTC BB: ARDM.OB), an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases, today announced that they have entered into a broad manufacturing services agreement whereby Sigma-Tau PharmaSource will provide Aradigm with clinical and commercial supplies of Pulmaquin(R). Pulmaquin is Aradigm's proprietary formulation of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).

Aradigm to Present at the Stifel Nicolaus 2013 Healthcare Conference
Business Wire - Mon Sep 09, 6:00AM CDT
Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that Nancy E. Pecota, Aradigm's Vice President, Finance and Chief Financial Officer, will present an overview of the Company at the Stifel Nicolaus 2013 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 12, 2013 at 10:20 am Eastern time.

Aradigm, Grifols Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 03, 2:15PM CDT
Aradigm Corporation announced the closing of an exclusive, worldwide license agreement with Grifols, S.A.

Smoking Cessation - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qr7jjs/smoking_cessation) has announced the addition of the "Smoking Cessation - Pipeline Review, H2 2013" report to their offering. 'Smoking Cessation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Smoking Cessation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smoking Cessation. Scope - A snapshot of the global therapeutic scenario for Smoking Cessation. - A review of the Smoking Cessation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Smoking Cessation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Aradigm Corporation GlaxoSmithKline plc Laboratoires Pierre Fabre SA Pfizer Inc. Targacept, Inc. CBio Limited Marinus Pharmaceuticals, Inc. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Royalty Pharma Selecta Biosciences, Inc. Embera NeuroTherapeutics, Inc. Celtic Pharmaceutical Holdings L.P. NAL Pharmaceuticals Ltd. BIOPROJET SCR For more information visit http://www.researchandmarkets.com/research/qr..._cessation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin(R)
Business Wire - Wed Aug 28, 6:00AM CDT
Grifols, S.A. (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS) ("Grifols") and Aradigm Corporation (OTC BB:ARDM.OB) ("Aradigm") today announced the closing of the transaction that includes the exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin(R)) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE). Aradigm has completed Phase 2b clinical trials in BE patients with Pulmaquin and Lipoquin.

Aradigm Corporation secures USD260,000 NIH grant to investigate new diagnoses tests of aspirations of gastrointestinal contents into respiratory tract
M2 - Mon Aug 12, 4:54AM CDT
Pharmaceutical company Aradigm Corporation (OTC BB:ARDM) revealed on Friday the receipt of a Small Business Initiative Research (SBIR) grant to investigate the development and validation of tests for gastro-esophageal reflux with aspirations into the respiratory tract.

OTC Daily Alert Stock Watch - Aradigm (OTCQB: ARDM )
WorldStockWire - Sat Aug 10, 8:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 61

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Chainlink, UBS Take $2 Trillion Notes Toward Onchain

Updated Category News Views 74

Paperwork is a lousy moat when a bank can automate the mess. Chainlink and UBS are putting that proposition to work in structured notes, a market with more than $2 trillion in outstanding notional and, frankly, an awful lot of operational clutter. Their production solution uses the Chainlink Runtime Environment, or CRE, to connect UBS systems, smart contracts, market data...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Caregiver Strategy Puts a Hard Truth on the Table Today

Updated Category News Views 35

Sixty-three million people carrying care responsibilities is not a side issue; it is a national load-bearing wall. The 2026 National Strategy to Support Family Caregivers arrives with that reality plainly in view, and frankly, it is overdue for the country to treat family care as core infrastructure rather than a private household problem somebody is expected to absorb...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 47

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 58

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 60

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 85

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 195

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading

Top 5 Most Recently Viewed Articles

Boots Group Wraps Up Consent Solicitation for Notes

Updated Category News Views 183

Consent Solicitation's Critical Role in Acquisition No time for dawdling—Boots Group's gathered up their consent cards for hefty senior secured notes, and we're talking close to a billion smackers here. It's a bold move to grease the wheels on looming acquisition maneuvers. We're looking at a €650 million and a £375 million stack of senior secured notes patiently...

Continue Reading
HUB Cyber Security Ltd. Welcomes Romke E. de Haan III

Updated Category News Views 120

HUB Cyber Security Ltd. Strengthens Leadership with New Appointment HUB Cyber Security Ltd. (NASDAQ: HUBC), a frontrunner in AI-driven cybersecurity solutions, has made a significant move by appointing Romke E. de Haan III as the Head of its Cybersecurity Strategy and Innovation Division. This pivotal role is expected to bolster the company's position within the North...

Continue Reading
Lisk EMpower Fund: Empowering Founders in Web3 Ventures

Updated Category News Views 177

Lisk EMpower Fund: A New Horizon for Web3 Startups The recently launched Lisk EMpower Fund is designed to support post-incubation Web3 startups in rapidly evolving markets, particularly in regions such as Africa, Latin America, and Southeast Asia. This initiative aims to bridge the gap in capital availability, providing opportunities for founders to achieve significant...

Continue Reading
BMO Capital Raises Datadog Price Target on Strong Revenue Outlook

Updated Category News Views 164

BMO Capital Shows Confidence in Datadog's Growth Recently, BMO Capital Markets demonstrated a strong belief in Datadog Inc (NASDAQ: DDOG), which operates a cloud-based monitoring and analytics platform. The firm raised its price target for the stock from $132.00 to $135.00 while maintaining an Outperform rating, reflecting their confidence in the company's ability to...

Continue Reading
Guru4Invest Introduces Revolutionary Security Upgrades

Updated Category News Views 555

Guru4Invest Strengthens Client Security with New Protocols In a significant move to bolster client safety and data integrity, Guru4Invest has rolled out advanced security protocols aimed at enhancing the protection of customer accounts and sensitive information. This decision reflects the company's steadfast commitment to security within the trading sector, showcasing...

Continue Reading